{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', 'An additional analysis will be conducted once the last subject completes the extension study to analyze', 'data collected at 18 and 24 months.', '12.1', 'DETERMINATION OF SAMPLE SIZE', 'A non-inferiority approach on response rate was used to estimate the sample size for this study, with', '\"response\" defined as > 50% reduction in pain on the NRS scale from baseline. The upper bound of a 2-', 'sided 95% CI will be calculated for the rate difference between treatments (Standard minus Test). If the', 'upper bound is less than (), then \"non-inferiority\" is achieved for the test treatment relative to standard', 'treatment, as described in the table below:', 'Success Rate of CRFA', 'Success Rate of', 'Non-Inferiority', 'Sample Size', '(based on 50% Pain', 'Standard (Based on', 'Margin ()', '5% Level of Significance', 'Score Reduction in VAS)', '30% Pain Score', '(2-sided)', 'Reduction in VAS)', '90% Statistical Power', \"62%'\", '*', '40%*', '5%', '134', '*', '- 14 Davis, et al, RAPM 2017, In Press /FDA clearance K163461', '** - 5 Chevalier, X et al. \"Single, intra-articular treatment with 6 ml Hylan G-F 20 in patients with symptomatic primary', 'osteoarthritis of the knee: a randomized, multi-center, double-blind, placebo controlled trial\" Ann Rheum Dis 2010 69: 113-119.', 'Assuming an attrition rate of 20%, 168 subjects enrolled into the study will yield 134 completers.', '12.1.1', 'Disposition of Subjects', 'The number and percentage of subjects entering the study will be presented. Reasons for any screen', 'failures and/or early terminations will be summarized. A flow chart will present the aggregate disposition', 'of subjects from Visit 1 (Screening Visit) through the final 24-month visit, including all subjects who cross', 'over from the viscosupplementation injection group to the CRFA denervation group.', '12.1.2 Protocol Deviations', 'Deviations from the protocol, including violations of inclusion/exclusion criteria, will be assessed as', '\"minor\" or \"major\" by the sponsor prior to database lock and analysis. Major deviations from the protocol', 'will lead to the exclusion of a subject from the Per-Protocol Set.', 'Certain clinical situations may require waivers for the safety of the subjects enrolled, integrity of the data', 'or scheduling conflicts. Any waiver request will be reviewed on an independent basis and must be', 'documented in writing prior to the event occurrence. Clinical decisions will be made by the medical', 'monitor.', 'Version #: 4.0', 'Page 37 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '12.2', 'DATASET DEFINITIONS', '12.2.1 Safety Set', 'All randomized subjects who receive CRFA or HA injection treatment will be included in the safety', 'analyses.', '12.2.2 Full-Analysis Set', 'All randomized subjects will be analyzed following the principle of intention-to-treat (ITT) provided they', 'received CRFA or HA injection treatment and had at least one effectiveness observation.', '12.2.3 Per-Protocol Set', 'All randomized subjects who are compliant with the study protocol (i.e., who do not experience any major', 'protocol deviations) and who receive CRFA or HA injection treatment and have at least one effectiveness', 'observation will be included in the Per-protocol Set.', 'The primary effectiveness endpoint analysis will be based on the Full Analysis Set, although a secondary', 'analysis will also be performed based upon the Per-Protocol Set (if there are differences), to assess the', 'sensitivity of the analysis to the choice of analysis population. The analyses of all other endpoints will be', 'based upon the Full Analysis Set only unless otherwise stated in the SAP. All safety analyses will be', 'based upon the Safety Set.', 'Crossover subjects that continue to meet all Inclusion/Exclusion criteria will be included in the Per-', 'protocol Set, and may be combined with CRFA randomized subjects for purposes of overall assessment', 'of the CRFA procedure.', '12.3 EFFECTIVENESS PARAMETER', '12.3.1 Primary Effectiveness Parameter', 'The primary effectiveness parameter is defined as the proportion of subjects whose knee pain is reduced', 'from baseline by > 50% based on the Numeric Rating Scale (NRS) at the 6-month visit.', '12.3.2 Secondary Effectiveness Parameters', 'Secondary Effectiveness Endpoint 1: The proportion of subjects whose knee pain is reduced from', 'baseline by > 50% based on the Numeric Rating Scale (NRS) at the 12-month visit.', 'Secondary Effectiveness Endpoint 2: The change in the WOMAC Score from baseline to the 6 month visit', 'and 12-month visit.', 'Version #: 4.0', 'Page 38 of 62', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}